Intestinal CD103⁺CD11b⁻ dendritic cells restrain colitis via IFN-γ-induced anti-inflammatory response in epithelial cells

ARBM Muzaki¹,³, P Tetlak¹,³, J Sheng¹, SC Loh¹, YA Setiagani¹, M Poidinger², F Zolezzi², K Karjalainen¹ and C Ruedl¹

A crosstalk between commensals, gut immune cells, and colonic epithelia is required for a proper function of intestinal mucosal barrier. Here we investigated the importance of two distinct intestinal dendritic cell (DC) subsets in controlling intestinal inflammation. We show that Clec9A–diphtheria toxin receptor (DTR) mice after depletion of CD103⁺CD11b⁻ DCs developed severe, low-dose dextran sodium sulfate (DSS)-induced colitis, whereas the lack of CD103⁺CD11b⁺ DCs in Clec4a4-DTR mice did not exacerbate intestinal inflammation. The CD103⁺CD11b⁻ DC subset has gained a functional specialization that allows them to repress inflammation via several epithelial interferon-γ (IFN-γ)-induced proteins. Among others, we identified that epithelial IDO1 and interleukin-18-binding protein (IL-18bp) were strongly modulated by CD103⁺CD11b⁻ DCs. Through its preferential property to express IL-12 and IL-15, this particular DC subset can induce lymphocytes in colonic lamina propria and in epithelia to secrete IFN-γ that then can trigger a reversible early anti-inflammatory response in intestinal epithelial cells.

INTRODUCTION

Intestinal mucosal surfaces, as the major interface between the body tissues and a potentially hostile outer environment, have evolved as a well-structured barrier against physical, chemical, and microbial insults. The epithelial layer, mucus, antimicrobial peptides, secreted immunoglobulin A, and innate and adaptive immune cells together form efficient and complex mucosal barrier (reviewed in ref. 1). All these components help to establish a beneficial “ecosystem” where a diverse and dense commensal community is tolerated, without immune attack for the benefit of the host. Perturbation of this mutualistic relationship can result in severe inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, and even more insidiously intestinal malignancies or metabolic syndromes.

The role of intestinal epithelial cells (IECs) in maintaining barrier function and in the pathogenesis of several common intestinal diseases such as IBD has been extensively studied.¹² In fact, enhanced gut epithelial permeability and leakage of luminal microbes across the barrier has been linked with IBD in humans and animals.⁴⁵

The contribution of myeloid cells such as dendritic cells (DCs) in regulating the mucosal barrier, such as epithelial integrity, production of bactericidal enzymes, or antimicrobial peptides, has not been established. It is possible that gut DCs, sentinels of mucosal immune responses, can also contribute in supporting intestinal barrier homeostasis.

Major myeloid cell subsets have been described in the colon lamina propria (LP) that differ in their ontogeny as well as in function.⁶⁷ There are at least two subsets of bona fide LP DCs that both express the mucosal integrin αE (CD103) β, but differ in their expression of CD11b.⁸ One subset, the CD103⁺ CD11b⁻ DCs, the main population in the colonic LP, is dependent on the transcription factors BATF3/IRF8/Id2 for its development⁹¹⁰ and is expressing the lectin Clec9A also termed DNGR1.¹¹ The second subset, the migratory CD103⁺ CD11b⁺ DCs, is IRF4 dependent and expresses the lectin Clec4a4 (also known as DCIR2)¹² and signal regulatory protein-ζ (SIRPζ).¹³

¹School of Biological Sciences, Nanyang Technological University, Singapore, Singapore and ²Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore. Correspondence: C Ruedl (ruedl@ntu.edu.sg)

²The first two authors equally contributed to this work.

Received 11 March 2015; accepted 15 June 2015; published online 15 July 2015. doi:10.1038/mi.2015.64
Lineage affiliation of the third CD11c⁺ CD103⁻ CD11b⁺ myeloid subpopulation is still controversial, i.e., do they belong to DC or macrophage lineage.14–16 Although different DC subpopulations have been described in the gut, their exact roles in controlling gut inflammatory responses or in protection against potential infections are still elusive.17 To assess their importance in the context of intestinal damage and inflammation, we exploited two diphtheria toxin receptor (DTR) transgenic mouse lines, Clec9A-DTR and Clec4a4-DTR, enabling us to in vivo ablate both bona fide DC subsets (CD103⁺ CD11b⁻ and CD103⁺ CD11b⁺ respectively) and test these mouse strains in a dextran sodium sulfate (DSS)-induced acute colitis model.18 Our findings show clearly that only mice lacking CD103⁺ CD11b⁻ DCs were highly susceptible to intestinal inflammation, whereas the lack of CD103⁺ CD11b⁺ DCs did not exacerbate intestinal inflammation. Here we propose a novel pathway mediated by CD103⁺ CD11b⁻ DCs that controls the expression of a series of interferon-γ (IFN-γ)-inducible proteins in intestinal epithelial cells including the anti-inflammatory indoleamine 2,3 dioxygenase (IDO1) enzyme and the decoy protein interleukin-18-binding protein (IL-18bp). Our results underscore the unique role of CD103⁺ CD11b⁻ DCs as major intestinal immune regulators and reveal an efficient cellular network between specific intestinal DC subsets, lymphocytes, and epithelial cells to control colonic inflammation.

RESULTS
Characterization of colon CD11chighMHCII⁺ myeloid cell subsets: Clec9A and Clec4a4 lectins are differentially expressed on distinct colon bona fide DC subsets
Mouse large intestine contains three distinct CD11chigh MHCII⁺ myeloid cell subsets that express CD103⁺ CD11b⁻, CD103⁻ CD11b⁺, or CD103⁻ CD11b⁺, respectively, as shown in Figure 1a. To further characterize and classify them, we generated genome-wide transcriptional profiles of sorted colon CD11chigh MHCII⁺ cells (Figure 1a,b) isolated from control (steady state) or DSS-treated mice (day 4). A hierarchical clustering of the differentially expressed genes using Pearson’s correlation and complete linkage showed a clear clustering of CD103⁺ CD11b⁻, CD103⁻ CD11b⁺, and CD103⁻ CD11b⁺ cells as visible in the principal component analysis plot (Figure 1c). CD103⁺ CD11b⁻ cells were delineated as bona fide DCs because of expression of elevated levels of transcription factors Irf8, Irf5, and Id2 and other markers such as Clec9A, Cd24, Flt3, Xcr1, and Itga2 (Figure 1d lower part, in red). Furthermore, our analysis clearly suggested the macrophage identity for CD103⁻ CD11b⁺ cells that differentially expressed the macrophage transcription factor MafB as well as other macrophage-related markers such as F4/80 (Emr1), Cd68, Cd14, Tir4, Lamp1, mannose receptor (Mrc1), Mp scavenger receptor (Msr1), chemokine receptor Cx3Cr1, matrix metalloproteinase (Mmp13, Mmp14), and complement receptors (C5r1 and C3r1) (Figure 1d middle part, in red). The third subset expressing both CD103 and CD11b markers displayed the highest levels of Irf4 and Clec4a4 and co-shared molecules, although at lower levels, such as Fli3, Ilf5, and Id2 with the bona fide CD103⁺ CD11b⁺ DC subset, and some myeloid-related markers with CD103⁻ CD11b⁺ cells such as granulocyte-macrophage colony stimulating factor 2 receptor (Csf2rb2), triggering receptor expressed on myeloid cells 1 (Trem-1), macrophage galactose N-acetylgalactosamine-specific lectin 2 (Mgl2), SIRP-α and -β (Sirpa, Sirpb1a, Sirpb1b), different lectins (Clec4a1, Clec4d, Clec4d, Clec10a), and Mmp12. Taken together, our results strongly suggest that colon CD11chighMHCII⁺ myeloid cells can be subdivided into two distinct bona fide DC subsets and into a distinct macrophage-related cell subpopulation. Interestingly, our microarray analysis did not show any major significant changes between distinct DC subset collected at steady state or under DSS treatment, most likely because of the early time point of chemical treatment (4 days).

We next validated whether DC subpopulations defined above express Clec9A and Clec4a4 by flow cytometry. After gating on CD11c⁺ MHCII⁺ cells, Clec9A-expressing cells were confirmed to be located in the CD103⁺ CD11b⁻ fraction, whereas Clec4a4 expression was detectable only in CD103⁺ CD11b⁺ DC subset (Supplementary Figure S1 online, upper panels). CD11cmMHCII⁺ macrophages did not express any of the Clec9A and Clec4a4 lectins (Supplementary Figure S1, lower panels). Therefore, Clec9A- and Clec4a4-DTR mice can be used to specifically ablate different subsets of LP DCs.

Efficient and specific in vivo ablation of gut DC subsets
CX3CR1GFP/Clec9A⁻ and CX3CR1GFP/Clec4a4-DTR mice were then tested to see whether they could be used to ablate intestinal DC subsets. Both transgenic mouse strains were injected twice with 20 ng g⁻¹ body weight DT (days −2 and −1) and subsequently analyzed for the presence of different colon and mesenteric lymph node (MLN) DC subsets. As shown in Figure 2a, DT-treated CX3CR1GFP/Clec9A-DTR mice efficiently ablated the CD11c⁺MHCII⁺ CD103⁺ CD11b⁻ DC subset in colon. In the MLN, both classical lymphoid organ-resident CD11cmMHCII⁺ CD8⁺ CD11b⁻ and LP-derived migratory CD11cmMHCII⁺ CD103⁺ CD11b⁻ disappeared upon DT treatment (Figure 2b). On the contrary, DT-treated CX3CR1GFP/Clec4a4-DTR mice reduced the CD11chighCD103⁺ CD11b⁺ DC fraction by 70% in the colon and by 50% in the MLN. Classical lymphoid organ-resident CD11cmMHCII⁺ CD8⁺ CD11b⁻ DC fraction was effectively diminished by 80% (Figure 2b). Interestingly, for unknown reasons, DT-treated CX3CR1GFP/Clec4a4-DTR mice, but not DT-treated CX3CR1GFP/Clec9A-DTR mice, also partially ablated the CD11cmMHCII⁺ CX3CR1high macrophage fraction as shown in Figure 2a, whereas the CD11cmMHCII⁺ CX3CR1int monocyte-derived macrophage fraction was unaffected. This unexpected ablation, however, had no functional consequences (see below). As Clec9A is also expressed in common DC progenitors and pre-dendritic cells (DCs) in the bone marrow,²⁹ the repetitive DT injections could possibly affect all DC subsets. To exclude this, we analyzed spleen and colon 15 days after the
first DT injection (followed by further DT injections at days 4 and 8) and could confirm the spleen CD11b⁺ DC subset as well as the CD103⁺ CD11b⁻ DCs in the colon were not affected in our Clec9A-DTR mouse. On the contrary, CD8⁺ DCs and CD103⁻ CD11b⁻ stayed efficiently ablated over the observation period (data not shown).

Clec9A⁺ CD103⁻ CD11b⁻ and Clec4a4⁺ CD103⁻ CD11b⁺ DCs localize differently in colon LP
We analyzed the localization of both DC populations in the colon LP during steady state as well as during early events of DSS-mediated colitis before any obvious onset of disease (day 4). To achieve this, proximal colon cryosections were costained
with anti-CD11c together with anti-Clec9A or anti-Clec4a4 antibodies. As shown in Figure 3 both Clec9A⁺ and Clec4a4⁺ DC subsets are colocalized in different areas of colonic innate lymphoid follicles (ILFs). SomeCX3CR1⁺ macrophages were also found in ILFs (data not shown). However, only Clec9A⁺ DCs together with the CX3CR1⁺ macropahes could be visualized abundantly in the LP under steady-state conditions, whereas the Clec4a4⁺ DC subset was absent (Figure 3b,c). The Clec4a4⁺ DC fraction did not become detectable in the LP even upon DSS treatment (Figure 3b, right panel), whereas a clear shift from CX3CR1<sup>high</sup> to CX3CR1<sup>int</sup> cells, presumably inflammatory monocytes, could be observed in the LP (Figure 3d,e). The ablation of targeted colonic LP DC subpopulations was also confirmed during DSS treatment (day 4). In fact, LP of Clec9A-DTR mice lacked the CD103<sup>+</sup>CD11b<sup>-</sup> DCs and accumulated CD103<sup>+</sup>CD11b<sup>+</sup> DCs, whereas, vice versa, in Clec4a4-DTR mice, CD103<sup>+</sup>CD11b<sup>-</sup> DCs were efficiently ablated whereas CD103<sup>+</sup>CD11b<sup>-</sup> DCs remained (Figure 3f). Confocal analysis of Clec9A⁺ and Clec4a4⁺ DC subsets in colon sections of DT-treated Clec9A- and Clec4a4-DTR mice also confirmed their ablation at steady state and after 4 days of DSS treatment (Supplementary Figure S2).

In summary, our data indicate that Clec9A⁺ DCs and CX3CR1⁺ macrophages/monocytes are present in both ILFs and LP compartment, whereas Clec4a4⁺ DC are restricted to ILFs and no major changes in DC anatomical redistribution (ILF vs. LP) could be detected during DSS treatment or in absence of one of the DC subset.

**Absence of Clec9A⁺ CD103⁺ CD11b⁻ DCs, but not of Clec4a4⁺ CD103⁺ CD11b⁺ DCs, aggravates DSS-induced colitis**

As changes of the mucosal barrier composition have long been identified in gastrointestinal pathologies, we analyzed both Clec9A- and Clec4a4-DTR strains in a DSS-mediated acute experimental colitis and compared the intensity of inflammation in mice with unperturbed intestinal DC repertoire. Therefore, we challenged 8-week-old DT-treated wild-type (WT), Clec9A-DTR, and Clec4a4-DTR mice with 2% DSS in drinking water for 7 days followed by water without DSS (for simplicity, DT-treated WT and Clec9A- and Clec4a4-DTR mice will be hereafter referred as WT, Clec9A-DTR, and Clec4a4-DTR mice if not otherwise stated). Using these experimental conditions, only mild colitis was induced in...
the controls, whereas in Clec9A-DTR mice, severe symptoms were observed already at earlier stages of colitis. In fact, Clec9A-DTR mice showed large weight loss over the course of DSS treatment (Figure 4a). The observed body weight reduction in Clec9A-DTR mice correlated with a shortened colon length (Figure 4b), increased rectal bleeding (Figure 4c), and enhanced CD11b+Ly6G+ neutrophil and CD11b+Ly6C+ inflammatory monocyte infiltrations in colon (Figure 4d,e).
On the other hand, under the same low-dose DSS treatment, Clec4a4-DTR mice displayed hardly any weight loss, no measurable colon shortening, and weak rectal bleeding. In fact, there was a clear trend that Clec4a4-DTR mice showed more resistance to colitis than WT mice (Figure 4a–c). This "protective" trend was observed not only at low DSS concentrations, but was also confirmed when we increased DSS to 5%. The body weight of WT mice was reduced significantly by 25%, whereas it hardly changed for Clec4a4-DTR mice. On the contrary, at concentration of 5% DSS, Clec9A-DTR mice succumbed to the treatment (Figure 4g).

Next we monitored the epithelial integrity in the presence or absence of different DC subsets. To do this DT-treated or untreated Clec9A- or Clec4a4-DTR transgenic mice were fed with 2% DSS for 7 days and epithelial permeability was scored at days 4 and 10 (3 days after the termination of DSS treatment) with fluorescein isothiocyanate (FITC)–dextran introduced by gavage. As predicted, at day 10, Clec9A-DTR-ablated mice showed greatly increased leakage of FITC–dextran in serum. Interestingly, epithelium of Clec4a4-DTR mice seemed to stay intact whereas that of WT mice showed signs of leakage (Figure 4f).
Taken together, CD103^+ CD11b^- ablated mice were highly susceptible to DSS-induced colitis, whereas no obvious inflammation was seen without DSS in this short DT treatment schedule in steady-state conditions (data not shown). On the other hand, ablation of CD103^+ CD11b^- and partial depletion of CX3CR1^{high} macrophages in the Clec4a4-DTR mouse conferred resistance in the development of DSS-induced colon inflammation. The protection was not mediated by the absence of CX3CR1^{high} cells because a CD169-DTR mouse in which this particular gut macrophage subpopulation can be ablated is susceptible to colitis with all typical signs: shortened colon, increased bleeding, and intestinal permeability (Figure 5a–e).

Ablation of Clec9A^+ DCs affects the expression of several IFN-γ-inducible genes in IECs

An elaborate interplay between gut microbiota, epithelial cell layer, and immune cells controls gut homeostasis and constrains overexuberant inflammatory responses. Beside the passive role as a physical barrier, the IECs express antimicrobial peptides and enzymes, essential for resistance against invasive bacteria as well as for maintenance of intestinal tolerance. To assess a possible IEC contribution to the severe DSS-induced inflammation observed in Clec9A-DTR mice, we next performed microarray-based comparisons of gene expression in IECs collected from untreated control WT, DSS-treated WT, and Clec9A-DTR mice. Interestingly, microarray analyses

![Figure 5 Depletion of CX3CR1^{high} macrophages leads to severe intestinal inflammation. (a) Flow cytometry analysis of different macrophage and dendritic cell (DC) subsets. CX3CR1-GFP-CD169-DTR and CX3CR1-GFP-WT mice were injected with DT (20 ng per g body weight) and analyzed the following day for the ablation profile of different CD11c^{high}MHC II^{high} DCs and CD11c^{int}MHC II^{high} macrophages, respectively. For DC profiling, anti-CD103 and anti-CD11b were used, whereas for macrophage profiling, cells were stained with anti-CD64 and monitored for CX3CR1 GFP expression. (b–e) Ablation of CX3CR1^{high} macrophages enhances susceptibility to dextran sodium sulfate (DSS)-induced colitis. Wild-type (WT) and CD169–diphtheria toxin receptor (DTR) mice were injected with 20 ng g^{-1} DT following the schedule described in Methods. (b) Body weight was monitored daily over a period of 15 days. Open circles: DT-treated WT control; filled circles: DT-treated CD169-DTR. Each group: n = 5. Values represent the mean ± s.d. Two independent experiments were performed with the same numbers of animals. (c) Fecal samples of DT-injected WT controls (open circles) and CD169-DTR (filled circles) mice were collected at day 8 upon DSS treatment and scored for blood content. Each group: n = 5. Student’s t-test significance: ***P < 0.001. (d) Measurement of colon length at day 8 (cm) of control WT mice (gray bar) and DSS-treated WT (white bar) or CD169 DTR (black bar) mice. Each group: n = 5. Values represent the mean ± s.d. (e) Intestinal permeability as determined by quantifying the amount of fluorescein isothiocyanate (FITC)--dextran levels (μg ml^{-1}) in the serum after its oral gavage. DT-injected WT (open circles) and CD169-DTR mice (filled circles) were tested at days 4 and 10 from the beginning of DSS treatment. For each group, 5–9 mice were analyzed.
of the intestinal epithelial fraction from DSS-treated WT mice revealed a clear upregulation of IFN-γ and a series of IFN-γ-inducible genes, such as IFN-γ-induced GTPases (e.g., Gvin1, Gbp4, Igtp, lgp1), IFN-γ-induced proteins (e.g., Ifit1, Ifit2, Ifit3, Ifit4), IFN-γ-induced regulatory factors (e.g., Irf1, Ifi77, and Ifi9), NOD-like receptor family CARD domain containing 5 (Nlrc5), IFN-γ-induced major histocompatibility complex (MHC) class II-related proteins (e.g., H2-DMb1, H2-Ab1,
Absence of Clec9A⁻/⁻ CD103⁺ CD11b⁻ DCs leads to diminished expression of IDO1 and IL-18bp in IECs during early stages of colitis

Our gene array results indicate a marked downregulation of two anti-inflammatory molecules, the enzyme Ido1 and the decoy protein IL-18bp, in DSS-treated Clec9A-DTR mice (Figure 6a).

It is well documented that the immune modulatory activity of IDO1 is critical in limiting DSS-induced inflammation.22,23 As IDO1 is expressed in mononuclear cells, especially in DCs, and in other cells such as epithelial cells, we first compared the levels of Ido1 expression between different LP DC subsets and colon IECs. At steady-state conditions, CD103⁺ CD11b⁻ DCs are the major Ido1-expressing cells in the colon, but after DSS exposure, Ido1 mRNA expression in IECs exceeded by almost 10-fold the level of DC expression (Figure 6c). Ido1 was also confirmed as the major enzyme involved in the tryptophan catabolism in the gut, as the expression of two other enzymes involved, Ido2 and tryptophan 2,3 dioxygenase (Tdo), were not detectable in IECs at steady state as well as during DSS treatment (Figure 6d). Notably, tissue damage caused by DSS-induced Ido1 expression in IECs within 24 h and its expression was subsequently maintained over the 6 days tested (Figure 6e). Because of this pronounced DSS-induced upregulation of Ido1 mRNA in colon IECs and the massive downregulation in Clec9A-DTR mice, we validated the gene array results by semiquantitative PCR analysis as well as by western blot. PCR analysis revealed hardly detectable expression of Ido1 and IL-18bp mRNA in colon IECs and the massive downregulation in Clec9A-DTR mice (Figure 6a) that underlines the surprising role of gut CD103⁺ CD11b⁻ Clec9A⁺ DCs in regulating the intestinal IFN-γ response during DSS-induced colitis.

Figure 7. IFN-γ⁻⁻ mice show enhanced susceptibility to dextran sodium sulfate (DSS)-induced colitis. Wild-type (WT) and interferon-γ (IFN-γ)⁻⁻ mice were treated as described in Methods. (a) Body weight was monitored daily over a period of 11 days. IFN-γ⁻⁻ mice were killed at day 8 because of severe body weight loss (>30%). White circles: CB57/BL6 control; black circles: IFN-γ⁻⁻ mice. Each group: n=5. Values represent the mean ± s.d. Two independent experiments were performed with the same numbers of animals. (b) Fecal samples of CB57/BL6 control and IFN-γ⁻⁻ mice were collected at day 7 upon DSS treatment and scored for blood content. Each group: n>7 mice. Student’s t-test significance: ****P<0.0001.

Altogether, these results highlight the unique property of CD103⁺ CD11b⁻ DCs in regulating the expression levels of IFN-γ-inducible immune regulatory molecules synthesized by IECs important for gut homeostasis. Consistently with our observation, IFN-γ-deficient mice are highly susceptible to DSS-treatment that underlines an essential protective function of IFN-γ in controlling early phases of intestinal inflammation. In fact, IFN-γ mice had to be terminated at day 8 because of massive body weight loss (<70%) and severe rectal bleeding (Figure 7a,b).

CD103⁺ CD11b⁻ DCs modulate IFN-γ production by LP CD4⁺ and CD8⁺ T cells and intraepithelial CD8⁺ T cells

As Ido1 and IL-18bp expression is reported to be controlled by IFN-γ,25,26 we first confirmed the expression of the IFN-γ receptor in IECs and CMT-93 colon epithelial cell line, as shown in Figure 8a, and then corroborated the IFN-γ-dependent Ido1 and IL-18bp upregulation in the CMT-93 cells (Figure 8b). Consistently, IECs obtained from DSS-treated IFN-γ⁻⁻ mice lack the upregulation of Ido1 and IL-18bp typically observed after the chemical treatment in WT mice (Figure 8c).
The observation that CD103⁺CD11b⁻ DCs control the levels of IFN-γ-inducible genes in IECs prompted us to characterize the cellular source of IFN-γ. As shown in Figure 8d, we analyzed different T-cell populations localized in the colon LP or epithelial layer for their capacity to produce IFN-γ during early stages of DSS treatment and tested whether its secretion is...

Figure 8  IDO1 and IL-18bp expression is modulated by interferon-γ (IFN-γ). (a) Colonocytes express IFN-γ receptor (IFN-γR). The ex vivo isolated colonocytes and CMT-93 colon epithelial cell line were analyzed by semiquantitative real-time PCR (RT-PCR) analysis for IFN-γ receptor expression. Hprt was used as an endogenous mRNA control. (b) IDO1 and IL-18bp expression is induced by IFN-γ. CMT-93 cells were stimulated overnight with 100 U ml⁻¹ IFN-γ and analyzed for Ido1 and IL-18bp expression by semiquantitative RT-PCR analysis. (c) IFN-γ⁻/⁻ mice do not upregulate Ido1 and IL-18bp epithelial expression upon dextran sodium sulfate (DSS) treatment. Intestinal epithelial cells (IECs) were collected from untreated or DSS-treated wild-type (WT) and IFN-γ⁻/⁻ mice and evaluated by semiquantitative RT-PCR. One representative sample from each experimental group of three mice is shown. SS, steady state. (d) Clec9A–diphtheria toxin receptor (DTR) mice have a decreased proportion of IFN-γ-expressing lamina propria (LP) T cells and intraepithelial lymphocytes (IELs). Representative flow cytometry plots of LP and IELs harvested from wild-type (WT) and Clec9A-DTR mice 4 days after DSS treatment and stained for CD4, CD8, and γδ T cell receptor (TCR), respectively (representative fluorescence-activated cell sorting (FACS) dot plot, right panel) and stained for intracellular IFN-γ. Quantification of LP CD4⁺ T cells, LP CD8⁺ T cells, LP CD4⁺ CD8⁺ T-cell fraction, γδ⁺, and CD8⁺ IELs expressing IFN-γ. N = 6–8 mice pooled from 2 independent experiments ± s.e.m. Student’s t-test significance: *P < 0.05, **P < 0.01, ***P < 0.001, NS, not significant. (e) Quantitative real-time PCR (qPCR) analysis of IL-15, IL-12p40, IL-12p35, and IL-13p19 expression in distinct colon dendritic cell (DC) subsets obtained from control WT mice: CD103⁺CD11b⁻, CD103⁺CD11b⁺, and CD103⁻CD11b⁻. Data are representative of 3 independent experiments with 10 mice pooled in each group.
controlled by CD103⁺ CD11b⁻ DCs. At steady state, intestinal T cells do not secrete IFN-γ, but an intestinal T cell-mediated IFN-γ response was induced in response to DSS treatment as shown in Figures 6b and 8d. Notably, we found that in the absence of this particular DC subset LP, CD4⁺ T and CD8⁺ T cells as well as intraepithelial CD8⁺ T cells were significantly impaired in their capacity to produce IFN-γ (Figure 8d), a reduction that correlates with the reduced levels of IFN-γ-inducible genes in IECs during early stages of intestinal inflammation. No significant difference in IFN-γ production was observed in the non-CD4/CD8 T-cell LP fraction.

Finally, we sought to identify the cytokines that link CD103⁺ CD11b⁻ DCs to the production of IFN-γ by intestinal lymphocytes. Interestingly, quantitative real-time PCR analysis of isolated MHCII⁺ CD11c⁺ myeloid cell subsets (CD103⁺ CD11b⁻, CD103⁺ CD11b⁺, CD103⁻ CD11b⁻) in colon revealed a differential expression pattern of cytokines. Only CD103⁺ CD11b⁻ DCs expressed IL-12p35/IL-12p40 (IL-12) and IL-15, both cytokines involved in supporting IFN-γ production of intestinal lymphocytes,²⁷,²⁸ whereas CD103⁺ CD11b⁺ DCs expressed IL-23p19/IL-12p40 (IL-12) (Figure 8e). DSS-mediated epithelial injury expanded the numbers of CD103⁺ CD11b⁻ DCs by almost twofold, but surprisingly, no additional enhancement of IL12p35 and IL-15 mRNA levels was observed after 4 days of DSS challenge (Supplementary Figure S3), although we cannot exclude a transient cytokine increase during the first days of DSS treatment.

Collectively, these results suggest that under tissue injury conditions mediated via DSS, expansion of IL-12- and IL-15-producing CD103⁺ CD11b⁻ DCs modulates the secretion of IFN-γ by intestinal lymphocytes that then triggers the expression of IFN-γ-inducible epithelial genes, including the well-characterized anti-inflammatory molecules like IDO1 and IL-18bp that contribute in containing intestinal inflammation. To test whether the reduced levels of IFN-γ-induced proteins such as IDO1 and IL-18bp contribute to colitis-prone phenotype observed in CD103⁺ CD11b⁻ DC-ablated mice, we treated WT and Clec9A-DTR mice with immunostimulatory oligonucleotides (ISS-ODNs) that have been shown to trigger IFN-γ-response and to limit disease severity in experimental colitis.²⁹,³⁰ Two injections of ISS-ODNs increased the IFN-γ levels in both mouse strains, WT and Clec9A-DTR, supporting the effectiveness of the treatment (Figure 9a). ISS-ODN-mediated IFN-γ increase not only restored epithelial Ido1 and IL-18bp expression in Clec9A-DTR mice (Figure 9b), but also clearly reverted the severe inflammatory intestinal response caused by the absence of CD103⁺ CD11b⁻ DCs. In fact, Clec9A-DTR mice did not show the typical severe weight loss observed upon DSS (2%) treatment in non-ISS-ODN-injected animals and behaved similarly to WT control mice (Figure 9c).

**DISCUSSION**

Functional mucosal barrier is lost in IBDs because of an uncontrolled inflammatory cascade arising from a number of interdependent and possibly sequential events involving both nonimmune cells, such as IECs, and immune cells, including DCs, ILCs, innate γ/δ T cells, and regulatory T cells.³¹ Despite extensive literature on this field, we still have gaps in our understanding of which mediator(s) play essential roles in disease onset. As DCs have been implicated as one of the major contributors in DSS-mediated colonic inflammation,³² we dissected in this study the contribution of distinct intestinal DC subsets in controlling intestinal inflammation and showed that CD103⁺ CD11b⁻ DC subset has a unique role in protecting the mucosal barrier.

In the gut LP, a complex network of myeloid cells, including several distinct subsets of DCs and macrophages,³³,³⁴ regulates the intestinal homeostasis.³⁵ Intestinal myeloid cells clearly differ, not only by their phenotype and by distinct developmental requirements, but also in their in vivo function. Based on our gene array analysis, we are confident to cluster colonic CD103⁺ CD11b⁻ and CD103⁺ CD11b⁺ cells as bona fide DCs and CD103⁻ CD11b⁺ cells as macrophage lineage because of their specific DC- or macrophage-related expression profiles, confirming the observations of others.³⁶–³⁸ Recently, when analyzed more in detail, CD103⁺ CD11b⁻ cells could be further separated clearly into a DC and a macrophage fraction based on phenotype, gene profile, and kinetics.³⁹,⁴⁰ Both *bona

---

**Figure 9** Immunostimulatory oligonucleotide (ISS-ODN) treatment limits the colitis severity in Clec9A–diphtheria toxin receptor (DTR) mice. DT-injected wild-type (WT) and Clec9A-DTR mice were injected intraperitoneally (i.p.) 10 μg of ISS-ODN at the start of the dextran sodium sulfate (DSS) treatment (2%) and 4 days later. (a) Interferon-γ (IFN-γ) response was measured in the serum collected at day 4. (b) Epithelial Ido1 and IL-18bp expression profile at steady-state or under DSS treatment. Representative samples of three WT and Clec9A-DTR mice are shown. (c) The body weight was monitored daily over a period of 10 days. Black circles: DT-treated WT control; white circles: DT-treated WT control + ISS-ODN; black squares: DT-treated Clec9A-DTR; white squares: DT-treated Clec9A-DTR + ISS-ODN; Each group: n = 6 mice from two independent experiments. Values represent the mean ± s.d. ND, not detectable.
CD11b+/CD103+ DCs substantially differ not only in their developmental programming, but possibly also in their biological functions as they express different patterns of, e.g., cytokines, chemokines, and pathogen recognition receptors.

Therefore, the comparison between two Clec9A- and Clec4a4-DTR mouse strains provided us valuable tools to further investigate the contribution of each DC subpopulation in gut homeostasis.

The differential expression of Clec9A and Clec4a4 lectins in DC subpopulations allowed us to visualize their anatomical location in the large intestine. Interestingly, at steady state, DC subsets are colocalized in isolated ILFs, whereas in the LP only abundant numbers of CD103+CD11b+DCs are present. On the other hand, the CD103+CD11b+DC cells were barely detectable in the LP. Therefore, our data suggest that the recently described motile CD103+CX3CR1+ DC subset in the small intestine that occupies the gut epithelium, samples bacteria from the intestinal lumen, and emigrates to the MLN via CCR7 upregulation is the Clec9A-expressing CD103+CD11b+DC subset. In addition, CD11c+MHCII+CX3CR1+ macrophages situated close to the intestinal epithelium represent a clear, phenotypically distinct subpopulation that outnumber the CD103+CD11b+DCs by 3–4-fold.

To investigate the contribution of each DC subset in intestinal physiology and disease, we induced mild DSS colitis in WT, Clec9A-DTR, and Clec4a4-DTR mice. Surprisingly, although Clec4a4-DTR mice did not show any colitis symptoms, Clec9A-DTR mice showed severe clinical symptoms marked by diarrhea, bloody stools, and consistent weight loss upon mild DSS treatment. This underlines for the first time the crucial role of CD103+CD11b−DCs in controlling intestinal inflammation. However, this finding contradicts with the phenotype described for Batf3−/−mice, lacking CD103+CD11b−DCs, that did not show any exacerbated inflammation during DSS-mediated colitis. Possible reasons for this could be mouse genetic background (129SvEv vs. BALB/c), gene knockout vs. DT-induced cell lineage ablation, or even different commensal gut microbiota. Moreover, a potential cytokine-driven alternative pathway in CD8+DC103+DC development observed in Batf3−/−mice in response to infections cannot be excluded in response to DSS challenge. Interestingly, so far, only gut macrophages and IL-23-secreting CD103+CD11b+DCs have been considered to be key players in the maintenance of gut defense and homeostasis. In particular, IL-10-conditioned intestinal CX3CR1+ macrophages were shown to contribute in maintenance of intestinal integrity, as CX3CR1−deficient mice with reduced numbers of CX3CR1+ macrophages resulted in severe colitis, bacterial translocation, and colitogenic Th17 responses. Our results underline the fundamental contribution of CD103+CD11b−DCs as additional members in arsenal in regulating intestinal homeostasis and protecting the gut mucosae.

Intestinal homeostasis involves IECs that provide physical segregation of commensal bacteria as well as integration of the microbial signals. Expression of pathogen recognition receptors, including members of the Toll-like receptor and NOD-like receptor family, allows them to sense commensal and pathogen-derived signals promoting epithelial homeostasis and repair as well as immune regulatory mucosal responses. As a result, antimicrobial peptides and mucus secretion reinforce the biochemical barrier. The physical and biochemical barrier provided by IECs is not only modulated by the commensal microbial community, but also by underlying mucosal immune cells. Myeloid cells, including macrophages and DCs, ILCs, and T effector cells, often via their secreted cytokines, regulate through complex cellular networks, intestinal epithelia host defenses, and barrier functions. For example, IL-23 produced by DCs regulates IL-22 secretion, a cytokine that mediates epithelial cell proliferation and wound healing, and controls epithelial antimicrobial peptide responses, important for the retention of both commensal and pathogens in the outer mucus layer. Other cytokines, such as IFN-γ, IL-17, and IL-10, can contribute to the pathogenesis of IBD by suppressing or aggravating intestinal inflammation and its associated clinical symptoms. As often the case for other pleiotropic cytokines, IFN-γ may also have multifaceted functions in controlling mucosal inflammation. On one hand, it can exert proinflammatory functions by exacerbating mucosal inflammation. On the other hand, in particular, at early stages of inflammation, IFN-γ may also have important homeostatic functions, for example, by stimulating Paneth cells to release antimicrobial peptides by modulating anti-inflammatory molecules like IDO1, decoy proteins such as IL-18bp, as well as by controlling goblet cell function. Furthermore, IFN-γ-induced epithelial MHC class II expression has been shown to be protective against colitis. The protective role of IFN-γ during DSS-mediated intestinal inflammation was also confirmed in IFN-γ-deficient mice that, in our hands, were highly susceptible to the chemical treatment. In addition, as observed in Clec9A-DTR mice, IFN-γ-deficient mice do not upregulate epithelial IDO1 and IL-18bp in response to DSS. Strikingly, our results are in complete disagreement with the colitis-resistant phenotype observed by Ito et al., however their results were obtained using a different IFN-γ-deficient mouse strain (Tagawa et al. vs. Dalton et al.). In addition, they used another molecular weight of DSS (5 vs. 40 kDa) to induce chemical-induced epithelial injury. Here, we have identified a novel mechanism of how a specific DC subset controls intestinal inflammation through the modulation of a series of IFN-γ-inducible genes in IECs, including IFN-γ-regulated factors (IRFs), MHC class II molecules, and related molecules such as invariant chain (CD74). Of particular relevance is the regulation of immunosuppressive molecules such as IDO1 and IL-18bp that are typically upregulated during intestinal inflammation. In fact, in the absence of CD103+CD11b−DCs, the level of IDO1, the rate-limiting enzyme of tryptophan catabolism in IECs plummets that is often associated with IBDs (e.g., ulcerative colitis and Crohn’s disease) including intestinal malignancies. Its expression levels have even been correlated with the severity of gastrointestinal diseases. Immunosuppressive effects of IDO1 are linked with decreased local...
concentrations of tryptophan and enhanced levels of its metabolites such as kynurenines that induce direct cell growth arrest and T-cell unresponsiveness.65,66 At steady-state conditions, we and others have shown that gut DCs, in particular the CD103⁺CD11b⁻ subset, are the major IDO1-expressing cells in the colon, maintaining intestinal homeostasis via the balance between FoxP3⁺ regulatory T cells and T helper type 1/17 effector cells.54,67 However, during intestinal inflammation, IECs, but not DCs, represent the major source of IDO1 activity possibly with the function to counterbalance tissue-damaging responses and to protect the epithelium from invading microbes. In effect, immunohistological analyses confirmed a specific IDO1 expression pattern in inflamed mucosa, in particular, where epithelia cells flank ulcers and border crypt abscesses.68

Furthermore, we could also observe that in the colitis-prone Clec9A-DTR mice another important decoy protein was reduced in IECs, namely the IL-18bp.69 Although the function of IL-18 in gut inflammation is controversial,70 it is clear that blocking its activity attenuates intestinal damage.24,71 The imbalance of the IL-18/IL-18bp ratio could lead to higher levels of active IL-18 resulting in exacerbation of intestinal inflammation that we observe in Clec9A-DTR mice. Interestingly, the dysregulation of microRNA-controlled insulin-like growth factor binding protein 5 (IGFBP5) in LP myofibroblasts lead to increased severity of DSS-induced colitis because of decreased availability of IGF that is needed for colonic epithelial repair.72 Therefore, cytokine-binding proteins seem to emerge as major regulators of epithelial integrity.

Through its capacity to secrete IL-12 and IL-15, the CD103⁺CD11b⁻ subset clearly affects IFN-γ production of LP CD4⁺ and CD8⁺ T cells as well as of intraepithelial CD8⁺ T cells. Importantly, when higher IFN-γ levels are restored by immunostimulatory DNA, the colitis-prone phenotype of Clec9A-DTR mice can be reverted.

In summary, here we propose CD103⁺CD11b⁻ DCs as the major regulators of intestinal homeostasis by controlling IFN-γ-induced anti-inflammatory proteins in IECs such as IDO1 and IL-18bp. Our results highlight CD103⁺CD11b⁻ DCs in addition to the anti-inflammatory CX3CR1hi macrophages as the key myeloid cells safeguarding the normal gut homeostasis.

Methods

Mouse strains. Clec9A-DTR mice were recently generated in our laboratory as described in Piva et al.73 using a BAC (bacterial artificial chromosome) recombineering approach. The Clec4a4-DTR mouse strain was obtained by gene targeting. In short, the IRES-DTR cassette followed by removable selection marker (PGK-NeoR) was inserted after the stop codon in the 3' untranslated region of Clec4a4 gene. After electroporation of the targeting construct, several BALB/c ES colonies carrying desired DTR insertion within 3’ untranslated region of Clec4a4 were established. Selected ES clones were subsequently used for blastocyst microinjection, leading to generation of chimeric animals and ultimately germline transmission of the modified allele. As controls, aged-matched transgenic negative littermates were used, as indicated. All original transgenic mouse strains are of BALB/c background (Supplementary Figure S4).

CX3CR1-GFP transgenic mice were originally generated by Dr D Littman (New York, NY) and were kindly provided by Florent Ginhoux (SgLn, A*Star, Singapore, Singapore). IFN-γ⁻/⁻ mice (strain B6.129S7-Ifngtm1TsJ) were obtained from The Jackson Laboratory (Bar Harbor, ME).

All transgenic mice were bred and housed under specific pathogen-free conditions in the Nanyang Technological University animal facility. This study was carried out in strict accordance with the recommendations of the NAACLAR (National Advisory Committee for Laboratory Animal Research) guidelines under the Animal & Birds (Care and Use of Animals for Scientific Purposes) Rules of Singapore. The protocol ARF SBS/NIE 0158AZ was approved by the institutional animal care and use committee of the Nanyang Technological University of Singapore.

Antibodies and flow cytometry. Fluorochrome-labeled anti-CD45, anti-CD3, anti-CD4, anti-CD8, anti-γ/δ T cell receptor, anti-CD11c, anti-CD103, anti-MHC class II, anti-Ly6G, anti-Ly6G, anti-Clec4a4 (also called 33D1 antigen or DCIR2,12 and anti-Clec9A (also known as DNGr-1)11,13 were purchased from BioLegend (San Diego, CA). Stained cells were analyzed on an LSRII or Fortessa FACS (BD Biosciences, San Jose, CA) and data were analyzed with FlowJo software (TreeStar, Ashland, OR).

Depletion and isolation of intestinal DC subsets and T cells in colon and MLNs. WT, Clec9A-DTR, and Clec4a4-DTR mice were injected intraperitoneally with 20 ng g⁻¹ DT at day −1. At day 0, colon and MLNs were collected. The colon was flushed with cold phosphate-buffered saline (PBS), and cut longitudinally in small pieces that were subsequently washed in Hank’s balanced salt solution containing 1 mM DTT at 37°C under shaking for 20 min. To remove the epithelium, colon pieces were incubated in Hank’s balanced salt solution containing 1.3 mM EDTA under shaking conditions at 37°C for 1 h. To enrich intraepithelial lymphocytes (IELs), a 67/44% Percoll (GE Healthcare Life Sciences, Singapore) gradient was performed. To isolate LP DCs, the remaining colon pieces were digested in serum-free Iscove’s modified Dulbecco’s medium and 0.1 mg ml⁻¹ Collagenase D (Roche Applied Science, Basel, Switzerland) at 37°C for another additional 1 h and 30 min. Digested pieces were gently passed five times through a cell strainer. The leukocyte population containing T cells and DCs was enriched by a 70/40% Percoll gradient. Low-density cells at the interface were harvested and further processed for stainings. MLNs were processed for DC isolation as described in Ruedl et al.73 via collagenase digestion.

Experimental acute colitis model: DSS treatment. Female WT (negative littersmates), Clec9A-DTR, and Clec4a4-DTR mice were injected at day −1 with 20 ng g⁻¹ DT and during the DSS treatment every 3 days. 2% DSS (50,000 Da, MP Biomedical, Santa Ana, CA) was supplied at day 0 ad libitum in the drinking water for 7 consecutive days with fresh DSS supplied every 3 days. At day 8, the DSS was replaced with drinking water. Body weight was monitored daily and fecal samples were collected between days 5 and 8. There were 6 mice per group in two independent experiments, for a total of 12 total mice per group.

Because of the direct toxic effect of DSS on epithelial cells that leads to a complete loss of surface epithelium, we induced a rather moderate colitis by administration of a low concentration of 2% DSS. At this dosage we did not observe a loss of surface epithelium in control mice at day 4 of DSS treatment, thus allowing the assessment of the barrier function of an intact epithelial layer.

Measurement of fecal blood. Fecal blood content was measured in fecal pellets collected at day 8 using the Hemoccult SENSA (Beckman Coulter, Brea, CA) following the manufacturer’s instructions.

Analysis of inflammatory cell infiltrations during acute colitis. Colon LP cells of WT, Clec9A-DTR, and Clec4a4-CX3CR1 (GFP) DTR mice were isolated as described before, stained with PerCP-Cy5.5-labeled
anti-CD11b, PE-labeled anti-Ly6C, and APC-labeled Ly6G antibodies, and analyzed by flow cytometry.

Intracellular IFN-γ cytokine staining. Isolated colon LP cells and IELs were stimulated with phorbol 12-myristate 13-acetate/ionomycin (2 h) and with Brefeldin A for additional 2 h and stained with anti-CD45, -CD3, -CD4, -CD8, and -γ/δ T cell receptor-specific antibodies. Subsequently, cells were permeabilized and fixed using the FOXP3 Staining Buffer Set according to the manufacturer’s instructions (eBioscience, San Diego, CA) and intracellularly stained with PE-labeled anti-IFN-γ. Stained cells were analyzed by flow cytometry gating of CD45- and CD3-expressing cells. Representative dot plots showing CD4/CD8 staining profile for LP cells and CD8/γ/δ staining profile for IELs are shown.

FITC–dextran intestinal permeability assay. Intestinal permeability was assessed by oral administration of FITC–dextran (4 kDa, Sigma-Aldrich, St Louis, MO), a macromolecule that is used as a permeability probe. All mice were gavaged at days 0, 4, and 10 after the start of DSS treatment with 60 mg per 100 g body weight FITC–dextran 4 h before blood collection. Whole blood was obtained by cardiac puncture at the time of killing, and FITC–dextran translocation was measured in sera by fluorometry. Dilutions of FITC–dextran in serum/PBS were used as a standard curve, and absorption was measured in a fluorometer at 488/535 nm emission.

Preparation of colonic DCs and microarray analysis. Colon MHC $^\ddagger$ CD11c$^\ddagger$ cells were sorted on the basis of CD103 and CD11b expression as follows: CD103$^+$ CD11b$^+$, CD103$^+$ CD11b$^-$, and CD103$^-$ CD11b$^+$.

Colon epithelial cell line. Murine colon epithelial cell line CMT-93 was obtained from ATCC (Manassas, VA) and grown as monolayer at 37 °C in complete Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum. Trypsin-treated cells were plated in 12-well plates and treated with 100 U ml$^{-1}$ recombinant IFN-γ for 24 h. Total RNA was extracted from CMT-93 cells and transcribed to cDNA as described above.

Immunofluorescence microscopy. The distal part of the colon was opened longitudinally, washed in cold PBS, embedded, snap-frozen in Tissue-Tek OCT medium (Sakura, Finetek, Alphen aan den Rijn, The Netherlands), and processed for 8 μm thick cryosections. After fixation in acetone, sections were rehydrated in PBS containing 2% fetal calf serum, blocked with 2% bovine serum albumin, and incubated with primary monoclonal antibodies as indicated in the correspondent legends. Stained sections were then washed in PBS containing 2% fetal calf serum and mounted in DAPI (4',6-diamidino-2-phenylindole)-containing antifade mountant (VECTASHIELD, Vector Laboratories, Burlingame, CA). In the case of colons obtained from CX3CR1 transgenic mice, mice were perfused with 2% paraformaldehyde containing 0.05% (v/v) Triton-X-100 and mounted in DAPI–containing antifade mountant (VECTASHIELD, Vector Laboratories). All images were obtained with identical settings at ×20 objective magnification as indicated in the legend using confocal microscope (Zeiss LSM510 META inverted, Goettingen, Germany).

Western blotting. IECs isolated from 3 DSS-treated WT or Clec9A−/− mice were pooled and lysed on ice in a lysis buffer consisting of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and protease inhibitors. After centrifugation at 10,000 g for 15 min at 4 °C, supernatants were collected. Protein concentrations were determined using NanoDrop Spectrophotometer (Wilmington, DE). Normalized samples were run on 10% Tris-glycine SDS-polyacrylamide gels using the Mini-Sub Cell GT system (Bio-Rad, Hercules, CA) and transferred onto nitrocellulose membranes (Bio-Rad). The membranes were subsequently blocked in PBS supplemented with 0.05% (v/v) Tween-20 (Sigma-Aldrich Pte. Ltd., Singapore).
Singapore) and 3% (w/v) nonfat milk (Bio-Rad) overnight at 4 °C and then incubated for 1 h with the primary antibody rat anti-mouse IDO1 (BioLegend) or polyclonal β-tubulin (Santa Cruz Biotechnology, Dallas, TX) antibody, respectively. The membranes were rinsed with PBS/Tween-20 and incubated with the corresponding HRP-labeled secondary antibodies. The presence of IDO1 (45 kDa) and tubulin (50 kDa) was confirmed by the enhanced chemiluminescence detection system (SignalFire, ECL reagent, Cell Signaling Technology, Danvers, MA).

**Treatment with immunostimulatory DNA (ISS-ODN).** Animals were treated with ISS-ODN (5′-TGACTGTGAACGTTCGAGATGA-3′) as described in Ciorba et al. Briefly, WT and Clec9A-DTR mice were injected with DT at day −1 and day 4 and treated with 2% DSS at day 0. ISS-ODN (10 μg) was injected intraperitoneally at day 0 and day 4. To confirm the efficacy of the ISS-ODN treatment, IFN-γ levels were measured in sera of treated animals through conventional enzyme-linked immunosorbent assay at day 4.

**Statistical analysis.** Statistical analysis was performed using GraphPad Prism software (La Jolla, CA). All values are expressed as the average ± s.d. or s.e.m. as indicated in the legend. All experiments were repeated as at least two to three independent experiments. Samples were analyzed using Student’s t-test (two tailed). A P-value of <0.05 was considered to be significant.

The microarray data are available in the Gene Expression Omnibus (GEO) database under the accession number GSE58446.

**SUPPLEMENTARY MATERIAL** is linked to the online version of the paper at http://www.nature.com/ni

**ACKNOWLEDGMENTS** We thank Monika Tetlak for the excellent mouse management and Shi Hui Foo Yoo for microarray sample preparation. This work is devoted to Erich Ruedl. This work was supported by National Medical Research Council grants NMRR/1253/2010, NMRC/CBGR/0023/2012, and MOE2014-T2-1-011 to C.R.

**AUTHOR CONTRIBUTIONS** A.R.B.M.M. and P.T. performed the experiments and interpreted the data; J.S., S.C.L., and Y.A.S. contributed to specific experiments; M.P. performed bioinformatics analysis; F.Z. analyzed and discussed the microarray data; K.K. and C.R. designed the experiments, interpreted the data, and wrote the manuscript.

**DISCLOSURE** The authors declared no conflict of interest.

© 2016 Society for Mucosal Immunology

**REFERENCES**

1. Brown, E.M., Sadarangani, M. & Finlay, B.B. The role of the immune system in governing host-microbe interactions in the intestine. *Nat. Immunol.* 14, 660–667 (2013).

2. Macdonald, T.T. & Monteleone, G. Immunity, inflammation, and allergy in the gut. *Science* 307, 1920–1925 (2005).

3. Ponda, P.P. & Mayer, L. Mucosal epithelium in health and disease. *Curr. Mol. Med.* 5, 549–556 (2005).

4. Schmitt, H. et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. *Gastroenterology* 116, 301–309 (1999).

5. Peeters, M. et al. Clustering of increased small intestinal permeability in families with Crohn’s disease. *Gastroenterology* 113, 802–807 (1997).

6. Hashimoto, D., Miller, J. & Merad, M. Dendritic cell and macrophage heterogeneity in vivo. *Immunity* 35, 323–335 (2011).

7. Bogunovic, M., Mortha, A., Muller, P.A. & Merad, M. Mononuclear phagocyte diversity in the intestine. *Immunol. Res.* 54, 37–49 (2012).

8. Bogunovic, M. et al. Origin of the lamina propria dendritic cell network. *Immunity* 31, 513–525 (2009).

9. Edelson, B.T. et al. Peripheral CD103 + dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells. *J. Exp. Med.* 207, 823–836 (2010).

10. Ginhoux, F. et al. The origin and development of nonlymphoid tissue CD103 + DCs. *J. Exp. Med.* 206, 3115–3130 (2009).

11. Sancho, D. et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. *Nature* 458, 909–913 (2009).

12. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. *Science* 315, 107–111 (2007).

13. Persson, E.K. et al. IRF4 transcription-factor-dependent CD103(+) CD11b(+) dendritic cells drive murine T helper 1 cell differentiation. *Immunity* 38, 958–969 (2013).

14. Schulz, O. et al. Intestinal CD103+ but not CX3CR1+ antigen sampling cells migrate in lymph and serve classical dendritic cell functions. *J. Exp. Med.* 208, 3101–3114 (2009).

15. Medina-Contreras, O. et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. *J. Clin. Invest.* 121, 4787–4795 (2011).

16. Weber, B., Saurer, L., Schenk, M., Dickgreber, N. & Mueller, C. CX3CR1 defines functionally distinct intestinal mononuclear phagocyte subsets which maintain their respective functions during homeostatic and inflammatory conditions. *Eur. J. Immunol.* 41, 773–779 (2011).

17. Cerovic, V., Bain, C.C., Movat, A.M. & Miling, S.W. Intestinal macrophages and dendritic cells: what’s the difference? *Trends Immunol.* 35, 270–277 (2014).

18. Perse, M. & Cesar, A. Dextran sulphate colitis mouse model: traps and tricks. *J. Biomed. Biotechnol.* 2012, 718617 (2012).

19. Schraml, B.U. et al. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. *Cell* 154, 843–858 (2013).

20. Zigmund, E. et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. *Immunity* 37, 1076–1090 (2012).

21. Purnama, C. et al. Transient ablation of alveolar macrophages leads to massive pathology of influenza infection without affecting cellular adaptive immunity. *Eur. J. Immunol.* 44, 2003–2012 (2014).

22. Gurtner, G.J., Newberry, R.D., Schoema, S.R., McDonald, K.G. & Stenson, W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. *Gastroenterology* 125, 1762–1773 (2003).

23. Schuhmann, D. et al. Interfering with interferon-γ signalling in intestinal epithelial cells: selective inhibition of apoptosis-maintained secretion of anti-inflammatory interleukin-18 binding protein. *Clin. Exp. Immunol.* 163, 65–76 (2011).

24. Svakumar, P.V. et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. *Gut* 50, 812–820 (2002).

25. Schmidt, S.V. & Schultze, J.L. New insights into IDO biology in bacterial and viral infections. *Front. Immunol.* 5, 384 (2014).

26. Hurgin, V., Novaick, D. & Rubinstein, M. The promoter of IL-18 binding protein: activation by an IFN-γ-reduced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. *Proc. Natl. Acad. Sci. USA* 99, 16967–16962 (2002).

27. Ebert, E.C. Interleukin 15 is a potent stimulant of intraepithelial lymphocytes. *Gastroenterology* 115, 1439–1445 (1998).

28. Fuchs, A. et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. *Immunity* 39, 769–781 (2013).

29. Rachmilewitz, D. & et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. *Gastroenterology* 122, 1428–1441 (2002).

30. Ciorba, M.A. et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. *J. Immunol.* 184, 3907–3916 (2010).

31. Peterson, L.W. & Artis, D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat. Rev. Immunol.* 14, 141–153 (2014).

32. Berndt, B.E., Zhang, M., Chen, G.H., Huffnagle, G.B. & Kao, J.Y. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. *J. Immunol.* 179, 6255–6262 (2007).
ARTICLES

33. Persson, E.K., Scott, C.L., Mowat, A.M. & Agace, W.W. Dendritic cell subsets in the intestinal lamina propria: ontogeny and function. *Eur. J. Immunol.* 43, 3098–3107 (2013).

34. Mildner, A. & Jung, S. Development and function of dendritic cell subsets. *Immunity* 40, 642–656 (2014).

35. Farache, J., Zigmond, E., Shahkar, G. & Jung, S. Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense. *Immunol. Cell. Biol.* 91, 232–239 (2013).

36. Miller, J.C. et al. Deciphering the transcriptional network of the dendritic cell lineage. *Nat. Immunol.* 13, 888–899 (2012).

37. Rivollier, A., He, J., Kole, A., Valatas, V. & Kelsall, B.L. Inflammation switches the differentiation program of Ly6GChi monocytes from anti-inflammatory macrophages to inflammatory dendritic cells in the colon. *J. Exp. Med.* 209, 139–155 (2012).

38. Watchmaker, P.B. et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. *Nat. Immunol.* 15, 98–108 (2014).

39. Bain, C.G. et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6GChi monocyte precursors. *Mucosal Immunol.* 6, 498–510 (2013).

40. Scott, C.L. et al. CCR2(+)CD103(–) intestinal dendritic cells develop from DC-committed precursors and induce interleukin-17 production by Tcells. *Mucosal Immunol.* 8, 327–339 (2015).

41. Farache, J. et al. Luminal bacteria recruit CD103 + dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation. *Immunity* 38, 581–595 (2013).

42. Nies, J.H. et al. CKC5R1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. *Science* 307, 254–258 (2005).

43. Chiappa, M., Rescigno, M., Huang, A.Y. & Germain, R.N. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. *J. Exp. Med.* 203, 2841–2852 (2006).

44. Tussiwand, R. et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. *Nature* 490, 502–507 (2012).

45. Zigmond, E. & Jung, S. Intestinal macrophages: well educated exceptions from the rule. *Trends Immunol.* 34, 162–168 (2013).

46. Mantovani, A. & Marchesi, F. IL-10 and macrophages orchestrate gut homeostasis. *Immunity* 40, 637–639 (2014).

47. Kinnebrew, M.A. et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. *Immunity* 36, 276–287 (2012).

48. Shouval, D.S. et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. *Immunity* 40, 706–719 (2014).

49. Zigmond, E. et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. *Immunity* 40, 720–733 (2014).

50. McCuckin, M.A., Linden, S.K., Sutton, P. & Florin, T.H. Mucin dynamics and enteric pathogens. *Nat. Rev. Microbiol.* 9, 265–278 (2011).

51. Bevins, C.L. & Salzman, N.H. Paneth cells, antimicrobial peptides and their role in mucosal innate immune defense. *Nat. Rev. Microbiol.* 9, 356–368 (2011).

52. Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. *J. Exp. Med.* 206, 1465–1472 (2009).

53. Vaishnava, S. et al. The antibacterial lectin REGligamma promotes the spatial segregation of microbiota and host in the intestine. *Science* 334, 255–258 (2011).

54. Ito, R. et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. *Clin. Exp. Immunol.* 146, 330–338 (2006).

55. Farin, H.F. et al. Paneth cell extrusion and release of antimicrobial products is directly controlled by immune cell-derived IFN-gamma. *J. Exp. Med.* 211, 1393–1405 (2014).

56. Takamura, M. et al. IDO1 plays an immunosuppressive role in 2,4,6-trinitrobenzene sulfate-induced colitis in mice. *J. Immunol.* 191, 3057–3063 (2014).

57. Songhet, P. et al. Stromal IFN-gammaR-signaling modulates goblet cell function during Salmonella Typhimurium infection. *PLoS One* 6, e22459 (2011).

58. Thelemann, C. et al. Interferon-gamma induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis. *PLoS One* 9, e86844 (2014).

59. Tagawa, Y., Sekikawa, K. & Ikawara, Y. Suppression of concanavalin A-induced hepatitis in IFN-gamma(–/–) mice, but not in TNF-alpha(–/–) mice: role for IFN-gamma in activating apoptosis of hepatocytes. *J. Immunol.* 159, 1418–1428 (1997).

60. Dalton, D.K., Pitts-Meek, S., Keshav, S., Figari, I.S., Bradley, A. & Stewart, T.A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. *Science* 259, 1739–1742 (1993).

61. Wolf, A.M. et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. *Clin. Immunol.* 113, 47–55 (2004).

62. Cheriayil, B.J. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. *Inflamm. Bowel Dis.* 15, 1391–1396 (2009).

63. Ciocca, M.A. Indoleamine 2,3-dioxygenase in intestinal disease. *Curr. Opin. Gastroenterol.* 29, 146–152 (2013).

64. Matteoli, G. et al. Gut CD103 + dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. *Gut* 59, 595–604 (2010).

65. Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. *J. Exp. Med.* 196, 447–457 (2002).

66. Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U. & Ferrara, G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. *J. Exp. Med.* 196, 459–468 (2002).

67. Dai, X. & Zhu, B.T. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. *J. Histochem. Cytochem.* 58, 17–28 (2010).

68. Ferdinand, L. et al. Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. *Int. J. Immunopathol. Pharmacol.* 21, 299–295 (2009).

69. Dinarello, C.A., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 binding protein. *Front. Immunol.* 4, 289 (2013).

70. Siegmund, B. Interleukin-18 in intestinal inflammation: friend and foe?. *Immunol. Cell. Biol.* 85, 300–302 (2010).

71. Siegmund, B. et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 281, R1264–R1273 (2001).

72. Chiu et al., P.R. et al. An essential mesenchymal function for mmp-14/145 in intestinal epithelial regeneration. *J. Cell. Physiol.* 157, 1104–1116 (2014).

73. Pla, L., Teltak, P., Claser, C., Karjalainen, K., Renia, L. & Ruell, C. Cutting edge: Clec9A + dendritic cells mediate the development of experimental cerebral malaria. *J. Immunol.* 189, 1128–1132 (2012).

74. Ciminisi, i. et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. *Blood* 112, 3264–3273 (2008).

75. Ruess, C., Kopf, M. & Bachmann, M.F. CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. *J. Exp. Med.* 189, 1875–1884 (1999).

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/